3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Wilms Tumor
1
Thyroid Cancer, Papillary
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Medulloblastoma
1
Glioma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
3
venetoclax
2
selpercatinib
2
obinutuzumab
2
ibrutinib
2
decitabine and cedazuridine drug combination
2
cedazuridine
2
Rituximab
2
Nivolumab
2
Midazolam
2
Ipilimumab
2
Decitabine
2
Crizotinib
2
zanubrutinib
1
trametinib
1
toripalimab
1
tocilizumab
1
tazemetostat
1
tagraxofusp
1
sotorasib
1
sacituzumab govitecan
1
romiplostim
1
revumenib
1
repotrectinib
1
prednisolone phosphate
1
prednisolone acetate
1
pralsetinib
1
polatuzumab vedotin
1
pirtobrutinib
1
olutasidenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Has announcements
×
entrectinib
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA